1
|
Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers (Basel) 2022; 14:cancers14040958. [PMID: 35205706 PMCID: PMC8870411 DOI: 10.3390/cancers14040958] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 02/03/2022] [Accepted: 02/08/2022] [Indexed: 02/05/2023] Open
Abstract
Simple Summary Epithelial ovarian cancer (EOC) is the most fatal gynecological cancer with poor survival rates and high mortality. EOC patients respond to standard platinum-based chemotherapy in the beginning, but relapse often due to chemoresistance. Ovarian cancer cells disseminate from the ovarian tumors and spread within the abdomen, where ascites fluid supports the growth and transition. Malignant ascites is present in a third of patients at diagnosis and is considered as a major source of chemoresistance, recurrence, poor survival, and mortality. Malignant ascites is a complex fluid that contains a pro-tumorigenic environment with disseminated cancer cells in 3D spheroids form. In this study, we established an ovarian cancer cell line and identified that 3D spheroids develop from the 2D monolayer, and the platinum-resistant phenotype develops due to the aberrant PI3K-AKT signaling in tumor cells. Furthermore, when we used a combinatorial approach of cisplatin with LY-294002 (a PI3K-AKT dual kinase inhibitor) to treat the cisplatin version of both MCW-OV-SL-3 and A-2780 cell lines, it prevented the 3D spheroid formation ability and also sensitized the cells for cisplatin. In brief, our results provided evidence to advance therapeutic approaches to treat cisplatin resistance in ovarian cancer patients. Abstract Ovarian cancer is the most lethal gynecological malignancy among women worldwide and is characterized by aggressiveness, cancer stemness, and frequent relapse due to resistance to platinum-based therapy. Ovarian cancer cells metastasize through ascites fluid as 3D spheroids which are more resistant to apoptosis and chemotherapeutic agents. However, the precise mechanism as an oncogenic addiction that makes 3D spheroids resistant to apoptosis and chemotherapeutic agents is not understood. To study the signaling addiction mechanism that occurs during cancer progression in patients, we developed an endometrioid subtype ovarian cancer cell line named ‘MCW-OV-SL-3’ from the ovary of a 70-year-old patient with stage 1A endometrioid adenocarcinoma of the ovary. We found that the cell line MCW-OV-SL-3 exhibits interstitial duplication of 1q (q21–q42), where this duplication resulted in high expression of the PIK3C2B gene and aberrant activation of PI3K-AKT-ERK signaling. Using short tandem repeat (STR) analysis, we demonstrated that the cell line exhibits a unique genetic identity compared to existing ovarian cancer cell lines. Notably, the MCW-OV-SL-3 cell line was able to form 3D spheroids spontaneously, which is an inherent property of tumor cells when plated on cell culture dishes. Importantly, the tumor spheroids derived from the MCW-OV-SL-3 cell line expressed high levels of c-Kit, PROM1, ZEB1, SNAI, VIM, and Twist1 compared to 2D monolayer cells. We also observed that the hyperactivation of ERK and PI3K/AKT signaling in these cancer cells resulted in resistance to cisplatin. In summary, the MCW-OV-SL3 endometrioid cell line is an excellent model to study the mechanism of cancer stemness and chemoresistance in endometrioid ovarian cancer.
Collapse
Affiliation(s)
- Deepak Parashar
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Anjali Geethadevi
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Sonam Mittal
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Lindsey A. McAlarnen
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Jasmine George
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Ishaque P. Kadamberi
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Prachi Gupta
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Denise S. Uyar
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Elizabeth E. Hopp
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Holli Drendel
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (H.D.); (K.M.B.)
| | - Erin A. Bishop
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - William H. Bradley
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Kathleen M. Bone
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (H.D.); (K.M.B.)
| | - Janet S. Rader
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
| | - Sunila Pradeep
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
- Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Pradeep Chaluvally-Raghavan
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (D.P.); (A.G.); (S.M.); (L.A.M.); (J.G.); (I.P.K.); (P.G.); (D.S.U.); (E.E.H.); (E.A.B.); (W.H.B.); (J.S.R.); (S.P.)
- Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- Correspondence:
| |
Collapse
|
2
|
PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci 2021; 22:ijms22041882. [PMID: 33668685 PMCID: PMC7918312 DOI: 10.3390/ijms22041882] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 01/23/2021] [Accepted: 01/28/2021] [Indexed: 12/19/2022] Open
Abstract
Many long noncoding RNAs have been implicated in tumorigenesis and chemoresistance; however, the underlying mechanisms are not well understood. We investigated the role of PRKAR1B-AS2 long noncoding RNA in ovarian cancer (OC) and chemoresistance and identified potential downstream molecular circuitry underlying its action. Analysis of The Cancer Genome Atlas OC dataset, in vitro experiments, proteomic analysis, and a xenograft OC mouse model were implemented. Our findings indicated that overexpression of PRKAR1B-AS2 is negatively correlated with overall survival in OC patients. Furthermore, PRKAR1B-AS2 knockdown-attenuated proliferation, migration, and invasion of OC cells and ameliorated cisplatin and alpelisib resistance in vitro. In proteomic analysis, silencing PRKAR1B-AS2 markedly inhibited protein expression of PI3K-110α and abrogated the phosphorylation of PDK1, AKT, and mTOR, with no significant effect on PTEN. The RNA immunoprecipitation detected a physical interaction between PRKAR1B-AS2 and PI3K-110α. Moreover, PRKAR1B-AS2 knockdown by systemic administration of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine nanoparticles loaded with PRKAR1B-AS2–specific small interfering RNA enhanced cisplatin sensitivity in a xenograft OC mouse model. In conclusion, PRKAR1B-AS2 promotes tumor growth and confers chemoresistance by modulating the PI3K/AKT/mTOR pathway. Thus, targeting PRKAR1B-AS2 may represent a novel therapeutic approach for the treatment of OC patients.
Collapse
|
3
|
Wang S, Gao J, Li Q, Ming W, Fu Y, Song L, Qin J. Study on the regulatory mechanism and experimental verification of icariin for the treatment of ovarian cancer based on network pharmacology. JOURNAL OF ETHNOPHARMACOLOGY 2020; 262:113189. [PMID: 32736044 DOI: 10.1016/j.jep.2020.113189] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Revised: 07/05/2020] [Accepted: 07/16/2020] [Indexed: 06/11/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Herba Epimedii (Berberidaceae) has the advantages of "nourishing the kidney and reinforcing the Yang". Many species in this genus have long been used in traditional Chinese medicine (TCM) and have been used as anticancer drugs in traditional Chinese herbal medicine formulations. Icariin, a major flavonoid glycoside extracted from Epimedium brevicornum Maxim, has been widely proven to exert an inhibitory effect on ovarian cancer (OC), and icariin can induce apoptosis and inhibit invasion and migration. However, the underlying mechanism remains unclear, so further research is necessary to verify its traditional use. AIM OF THE STUDY This study aimed to explore the regulatory mechanism of icariin in the biological network and signalling pathway of OC through network pharmacology and cytological experiments. METHODS Public databases and R × 3.6.2 software were adopted to predict the potential targets, construct the protein-protein interaction (PPI) network, and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. After the network pharmacological analysis, cytological experiments, real-time quantitative PCR (qPCR) and Western blot (WB) analyses were used to verify the key signalling pathway. RESULTS The targets related to treatment were TNF, MMP9, STAT3, PIK3CA, ERBB2, MTOR, IL2, PTGS2, KDR, and F2. GO and KEGG enrichment analyses indicated that various kinases and the PI3K/AKT signalling pathway were the most enriched molecules and pathways. Icariin inhibited OC SKOV3 cell proliferation, migration and invasion in vitro and promoted apoptosis by inhibiting the PI3K/AKT signalling pathway. CONCLUSION Icariin promotes apoptosis and suppresses SKOV3 cell activities through the PI3K-Akt signalling pathway. This research not only provides a theoretical and experimental basis for more in-depth studies but also offers an efficient method for the rational utilization of a series of icariin flavonoids as anti-tumour drugs.
Collapse
Affiliation(s)
| | | | - Qingyu Li
- Jinan University, Guangzhou, 510632, China
| | | | - Yanjin Fu
- Jinan University, Guangzhou, 510632, China
| | | | - Jiajia Qin
- Jinan University, Guangzhou, 510632, China.
| |
Collapse
|
4
|
Yang PL, Liu LX, Li EM, Xu LY. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy. Cancers (Basel) 2020; 12:cancers12092459. [PMID: 32872659 PMCID: PMC7564975 DOI: 10.3390/cancers12092459] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 08/25/2020] [Accepted: 08/27/2020] [Indexed: 02/05/2023] Open
Abstract
Chemoradiotherapy is one of the most effective and extensively used strategies for cancer treatment. Signal transducer and activator of transcription 3 (STAT3) regulates vital biological processes, such as cell proliferation and cell growth. It is constitutively activated in various cancers and limits the application of chemoradiotherapy. Accumulating evidence suggests that STAT3 regulates resistance to chemotherapy and radiotherapy and thereby impairs therapeutic efficacy by mediating its feedback loop and several target genes. The alternative splicing product STAT3β is often identified as a dominant-negative regulator, but it enhances sensitivity to chemotherapy and offers a new and challenging approach to reverse therapeutic resistance. We focus here on exploring the role of STAT3 in resistance to receptor tyrosine kinase (RTK) inhibitors and radiotherapy, outlining the potential of targeting STAT3 to overcome chemo(radio)resistance for improving clinical outcomes, and evaluating the importance of STAT3β as a potential therapeutic approach to overcomes chemo(radio)resistance. In this review, we discuss some new insights into the effect of STAT3 and its subtype STAT3β on chemoradiotherapy sensitivity, and we explore how these insights influence clinical treatment and drug development for cancer.
Collapse
Affiliation(s)
- Ping-Lian Yang
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China; (P.-L.Y.); (L.-X.L.)
- Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China
| | - Lu-Xin Liu
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China; (P.-L.Y.); (L.-X.L.)
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, Guangdong, China
| | - En-Min Li
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China; (P.-L.Y.); (L.-X.L.)
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, Guangdong, China
- Correspondence: (E.-M.L.); (L.-Y.X.); Tel.: +86-754-88900460 (L.-Y.X.); Fax: +86-754-88900847 (L.-Y.X.)
| | - Li-Yan Xu
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China; (P.-L.Y.); (L.-X.L.)
- Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China
- Correspondence: (E.-M.L.); (L.-Y.X.); Tel.: +86-754-88900460 (L.-Y.X.); Fax: +86-754-88900847 (L.-Y.X.)
| |
Collapse
|
5
|
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers (Basel) 2019; 11:cancers11070949. [PMID: 31284467 PMCID: PMC6679095 DOI: 10.3390/cancers11070949] [Citation(s) in RCA: 96] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 06/10/2019] [Accepted: 06/30/2019] [Indexed: 02/07/2023] Open
Abstract
Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.
Collapse
|
6
|
Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer. Pathol Res Pract 2019; 215:152520. [PMID: 31288947 DOI: 10.1016/j.prp.2019.152520] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2019] [Revised: 06/03/2019] [Accepted: 06/26/2019] [Indexed: 01/01/2023]
Abstract
BACKGROUND AND PURPOSE The PI3K pathway is an important signaling network that regulates key cell functions such as cell growth, proliferation and survival. PIK3CA mutations are found in a variety of human cancers. This study aimed to analyze the effect of interactions between PIK3CA rs2699887, rs3976507, rs6443626 single nucleotide polymorphisms (SNPs), and the environment on the risk of Chinese Han ovarian cancer. METHODS Sanger sequencing was used to analyze the PIK3CA rs2699887, rs3976507, rs6443626 genotypes in 350 Chinese Han ovarian cancer patients and 350 control individuals, and the expression of PIK3CA protein was detected in 117 ovarian cancer patients. RESULTS In subjects with age ≥60 years, Number liveborn ≤ 3, no smoking, no alcohol, and no family history of ovarian cancer, the risk of ovarian cancer of the rs2699887 T allele carriers were increased (all p < 0.05). In subjects with obesity (BMI ≥ 24 kg/m2), Number liveborn ≤3, no smoking, no alcohol, and no family history of ovarian cancer, the risk of ovarian cancer of rs3976507 T allele carriers and rs6443626 C allele carriers were increased (all p < 0.05). PIK3CA protein expression level in PIK3CA rs2699887 C > T, rs3976507 C > T, rs6443626 T > C locus homozygotes was significantly higher than that in heterozygotes (p < 0.05). CONCLUSION Interaction between PIK3CA rs2699887 SNP and age, number of liveborn, tobacco, alcohol, a family history of ovarian cancer and other factors are associated with ovarian cancer risk. Interaction between PIK3CA rs3976507 and rs6443626 loci, and factors such as BMI, number of liveborn, tobacco, alcohol, and family history of ovarian cancer are associated with ovarian cancer risk.
Collapse
|